TABLE 3.
Inhibitory activities of lipopeptide fusion inhibitors against T-20-resistant HIV-1 mutants, HIV-2 isolates, and SIV isolatesa
| Env | Mean IC50 (nM) ± SD |
|||
|---|---|---|---|---|
| T-20 | LP-40 | LP-50 | LP-51 | |
| T-20 sensitive: NL4-3D36G | 13.65 ± 0.48 | 0.61 ± 0.07 | <0.01 | <0.01 |
| T-20 resistant | ||||
| NL4-3WT | 152.23 ± 15.28 | 43.94 ± 12.29 | 0.08 ± 0.02 | 0.03 ± 0 |
| NL4-3I37T | 1,001.19 ± 55.94 | 349.57 ± 95.56 | 1.07 ± 0.16 | 0.59 ± 0.04 |
| NL4-3V38A | 2,780 ± 176.55 | 1,812.67 ± 496.51 | 6.53 ± 0.37 | 1.77 ± 0.24 |
| NL4-3V38M | 1,319.73 ± 33.1 | 2,747 ± 758.5 | 1.45 ± 0.47 | 0.4 ± 0.19 |
| NL4-3Q40H | 2,147.37 ± 447.3 | 1,293.5 ± 364.83 | 3.76 ± 0.66 | 0.58 ± 0.05 |
| NL4-3N43K | 729.12 ± 79.37 | 534.77 ± 169.81 | 5.87 ± 0.73 | 0.99 ± 0.14 |
| NL4-3G36S/V38M | 565.17 ± 57.28 | 604.52 ± 142.66 | 1.76 ± 0.08 | 0.38 ± 0.06 |
| NL4-3I37T/N43K | >4,200 | 3,296 ± 260.62 | 142.03 ± 166.5 | 13.11 ± 1.08 |
| NL4-3V38A/N42T | 2,756 ± 831.37 | 1,745.13 ± 84.18 | 60.32 ± 7.89 | 8.3 ± 0.88 |
| NL4-3E49K/N126K | 470.97 ± 34.19 | 648.93 ± 21.12 | 0.16 ± 0.03 | 0.1 ± 0.03 |
| HIV-2 or SIV | ||||
| HIV-2ROD | 496.73 ± 14.53 | 1,582.33 ± 271.65 | 0.09 ± 0.01 | 0.08 ± 0.02 |
| HIV-2ST | 1,395.44 ± 429.91 | >5,000 | 7.01 ± 0.75 | 1.7 ± 0.13 |
| SIV239 | 353.13 ± 18.6 | 435.33 ± 19.6 | 0.05 ± 0.01 | 0.04 ± 0.01 |
| SIVPBJ | 939.83 ± 125.77 | 1,695.33 ± 265.44 | 0.06 ± 0.01 | 0.07 ± 0.01 |
| SHIV | ||||
| SHIVSF162P3 | 4.94 ± 0.65 | 1.23 ± 0.15 | 0.07 ± 0 | 0.09 ± 0 |
| SHIV1157 | 11.48 ± 1.31 | 23.68 ± 4.7 | 0.04 ± 0 | 0.04 ± 0.01 |
| Control Env: VSV | >2,000 | >2,000 | >2,000 | >2,000 |
a
The assay was performed in triplicate and was repeated three times.